WeVote
Log In

Bill

Bill

HF 4064

Commissioner of health directed to study and report on activities to support innovations in cell and gene therapy to treat rare diseases, report required, and money appropriated.

2025-2026 Regular Session Introduced by Jeff Backer and 9 co-sponsors

Minnesota health commissioner studies state support for cell and gene therapy innovation to treat rare diseases, reports findings, receives appropriated funding.

Author added Torkelson
#appropriations #healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · HF 4064

Legislative bill overview

HF 4064 directs Minnesota's Commissioner of Health to conduct a comprehensive study on how the state can support innovations in cell and gene therapy for treating rare diseases. The bill requires a formal report on findings and appropriates funding to support this initiative.

Why is this important

Cell and gene therapies represent cutting-edge medical treatments that can address previously untreatable rare diseases, but they face significant barriers including high costs, regulatory complexity, and limited market incentives. By studying state-level support mechanisms, Minnesota could position itself as a hub for these therapies while potentially improving patient access and attracting biotech investment and talent.

Potential points of contention

  • Cost and fiscal impact: The bill appropriates unspecified funding; critics may question whether state resources should subsidize therapies that are often privately developed and extremely expensive
  • Scope and feasibility: Questions about whether state-level support can meaningfully impact rare disease treatment development versus federal oversight through FDA and NIH
  • Market distortion concerns: Some may argue state support for specific medical sectors could create unfair advantages or conflicts with free market principles

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.